alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
COMPANY'S BALANCE SHEET AS OF SEPTEMBER 30, 2000 AND STATEMENTS OF OPERATIONS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2000 AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FINANCIAL STATEMENTS REPORTED ON FORM 10-Q.
</LEGEND>
<MULTIPLIER> 1

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                             314
<SECURITIES>                                         0
<RECEIVABLES>                                    6,603
<ALLOWANCES>                                     (124)
<INVENTORY>                                      2,170
<CURRENT-ASSETS>                                 9,705
<PP&E>                                           1,995
<DEPRECIATION>                                 (1,767)
<TOTAL-ASSETS>                                  16,180
<CURRENT-LIABILITIES>                           12,694
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         5,384
<OTHER-SE>                                     (1,984)
<TOTAL-LIABILITY-AND-EQUITY>                    16,180
<SALES>                                         14,372
<TOTAL-REVENUES>                                14,455
<CGS>                                           11,466
<TOTAL-COSTS>                                   11,466
<OTHER-EXPENSES>                                 3,916
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 413
<INCOME-PRETAX>                                (1,340)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            (1,340)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (1,340)
<EPS-BASIC>                                      (.23)
<EPS-DILUTED>                                    (.23)


</TABLE>
* Pursuant to 5 T H C IR . R. 47.5, the court has determined that

this opinion should not be published and is not precedent except under the limited circumstances set forth in 5 TH C IR . R. 47.5.4.

IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 97-20128 Conference Calendar

UNITED STATES OF AMERICA, Plaintiff-Appellee,

versus DAVID LEE EDDS, Defendant-Appellant.

- - - - - - - - - - Appeal from the United States District Court for the Southern District of Texas USDC No. H-96-CR-191-1

- - - - - - - - - - October 22, 1997 Before POLITZ, Chief Judge, and WIENER and DENNIS, Circuit Judges.
PER CURIAM: * David Lee Edds appeals his guilty-plea conviction for possession a firearm in violation of 18 U.S.C. § 922(g)(1). Edds argues that the federal government cannot, consistent with the Interstate Commerce Clause, the Tenth Amendment, and in the wake of United States v. Lopez , 115 S. Ct. 1624 (1995), punish a felon’s mere possession of a firearm that has traveled in interstate commerce at some unspecified time in the past because such possession lacks a sufficient nexus with interstateNo. 97-20128 -2- commerce. Section 922(g)(1) has been consistently upheld as

constitutional. See Scarborough v. United States , 431 U.S. 563 (1977); United States v. Kuban , 94 F.3d 971, 973 (5th Cir. 1996), cert. denied , 117 S. Ct. 716 (1997); United States v. Rawls , 85 F.3d 240, 242 (5th Cir. 1996).
AFFIRMED.
IV 

114TH CONGRESS 

1ST SESSION H. RES. 44 

Amending the Rules of the House of Representatives to permit Delegates 

and the Resident Commissioner to the Congress to cast votes in the 

Committee of the Whole House on the state of the Union. 

IN THE HOUSE OF REPRESENTATIVES 

JANUARY 22, 2015 

Mr. HOYER submitted the following resolution; which was referred to the 

Committee on Rules 

RESOLUTION 

Amending the Rules of the House of Representatives to 

permit Delegates and the Resident Commissioner to the 

Congress to cast votes in the Committee of the Whole 

House on the state of the Union. 

1 Resolved, 

2 SECTION 1. VOTING BY DELEGATES AND RESIDENT COM3 MISSIONER IN COMMITTEE OF THE WHOLE. 

4 (a) PERMITTING VOTES TO BE CAST.—Clause 3(a) 

5 of rule III of the Rules of the House of Representatives 

6 is amended by inserting before the first sentence the fol7 lowing: ‘‘In a Committee of the Whole House on the state 

8 of the Union, each Delegate and the Resident CommisVerDate Sep 11 2014 22:33 Jan 22, 2015 Jkt 049200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\HR44.IH HR44

asabaliauskas on DSK5VPTVN1PROD with BILLS
2 

•HRES 44 IH 

1 sioner shall possess the same powers and privileges as 

2 Members of the House.’’. 

3 (b) APPOINTMENT OF CHAIR.—The first sentence of 

4 clause 1 of rule XVIII of the Rules of the House of Rep5 resentatives is amended by striking ‘‘Member’’ and insert6 ing ‘‘Member, Delegate, or the Resident Commissioner’’. 

7 (c) REPEATING OF CERTAIN VOTES.—Clause 6 of 

8 rule XVIII of the Rules of the House of Representatives 

9 is amended by adding at the end the following new para10 graph: 

11 ‘‘(h) Whenever a recorded vote on any question has 

12 been decided by a margin within which the votes cast by 

13 the Delegates and the Resident Commissioner have been 

14 decisive, the Committee of the Whole shall rise and the 

15 Speaker shall put such question de novo without inter16 vening motion. Upon the announcement of the vote on 

17 that question, the Committee of the Whole shall resume 

18 its sitting without intervening motion.’’. 

Æ 


asabaliauskas on DSK5VPTVN1PROD with BILLS
<PAGE>   1
 
                                                                    EXHIBIT 23.1
 
                       CONSENT OF INDEPENDENT ACCOUNTANTS
 
     We hereby consent to the incorporation by reference in the prospectuses
constituting part of the Registration Statement on Form S-8 listed below of RMI
Titanium Company of our report dated January 23, 1998, appearing on page 23 of
this annual report on Form 10-K.
 
     File No. 33-36248 Relating to the RMI 1989 Stock Option Incentive Plan
 
     File No. 33-38340 Relating to the RMI Bargaining Unit Employees Savings and
     Investment Plan
 
     File No. 33-38339 Relating to the RMI Savings and Investment Plan
 
     File No. 33-63025 Relating to the RMI Titanium Company 1995 Stock Plan
 
Price Waterhouse LLP
Pittsburgh, Pennsylvania
March 27, 1998
P. 1 

# OAR Box 1796 Prepped by Keeia Richards


### Document

Number: 

# 5DVI-B- 2 Docket Number: 

# A-90-3 7

Printed 10/31/2008 4:20:37

PM Sheet 51 of 107P. 2 A-90-3 7 VI-B- 2 Thi s documen

t ha s bee n moved to IV-B-0 3 a

t th e reques t o f the projec t

officer . I t wa s incorrectl y categorize d originally .
<TABLE> <S> <C>

<ARTICLE> 9
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-END>                               SEP-30-1996
<CASH>                                           3,156
<INT-BEARING-DEPOSITS>                           7,412
<FED-FUNDS-SOLD>                                     0
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                     57,746
<INVESTMENTS-CARRYING>                          28,304
<INVESTMENTS-MARKET>                            27,381
<LOANS>                                        378,844
<ALLOWANCE>                                      5,470
<TOTAL-ASSETS>                                 492,779
<DEPOSITS>                                     368,332
<SHORT-TERM>                                    21,675
<LIABILITIES-OTHER>                              8,014
<LONG-TERM>                                     15,175
<COMMON>                                             0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                         36
<OTHER-SE>                                      79,547
<TOTAL-LIABILITIES-AND-EQUITY>                 492,779
<INTEREST-LOAN>                                  8,076
<INTEREST-INVEST>                                1,540
<INTEREST-OTHER>                                     0
<INTEREST-TOTAL>                                 9,616
<INTEREST-DEPOSIT>                               4,606
<INTEREST-EXPENSE>                               5,227
<INTEREST-INCOME-NET>                            4,389
<LOAN-LOSSES>                                      200
<SECURITIES-GAINS>                                (15)
<EXPENSE-OTHER>                                  4,672
<INCOME-PRETAX>                                    158
<INCOME-PRE-EXTRAORDINARY>                         158
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                       207
<EPS-PRIMARY>                                     0.08
<EPS-DILUTED>                                     0.08
<YIELD-ACTUAL>                                    3.76
<LOANS-NON>                                      4,468
<LOANS-PAST>                                         0
<LOANS-TROUBLED>                                     0
<LOANS-PROBLEM>                                      0
<ALLOWANCE-OPEN>                                 5,315
<CHARGE-OFFS>                                       51
<RECOVERIES>                                         6
<ALLOWANCE-CLOSE>                                5,470
<ALLOWANCE-DOMESTIC>                             5,470
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                              0
        

</TABLE>
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
The schedule contains summary financial information extracted from 1999 Broadway
Associates Limited Partnership and is qualified in its entirety by reference to
such financial statements.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                                DEC-31-1999
<PERIOD-START>                                   JAN-01-1999
<PERIOD-END>                                     DEC-31-1999
<CASH>                                             5,722,000<F1>
<SECURITIES>                                               0
<RECEIVABLES>                                              0
<ALLOWANCES>                                               0
<INVENTORY>                                                0
<CURRENT-ASSETS>                                           0
<PP&E>                                            50,659,000
<DEPRECIATION>                                    18,159,000
<TOTAL-ASSETS>                                    42,233,000
<CURRENT-LIABILITIES>                                      0
<BONDS>                                           37,000,000
<PREFERRED-MANDATORY>                                      0
<PREFERRED>                                                0
<COMMON>                                                   0
<OTHER-SE>                                         2,796,000
<TOTAL-LIABILITY-AND-EQUITY>                      42,233,000
<SALES>                                                    0
<TOTAL-REVENUES>                                   9,966,000
<CGS>                                                      0
<TOTAL-COSTS>                                      7,567,000
<OTHER-EXPENSES>                                           0
<LOSS-PROVISION>                                           0
<INTEREST-EXPENSE>                                 2,736,000
<INCOME-PRETAX>                                     (301,000)
<INCOME-TAX>                                               0
<INCOME-CONTINUING>                                 (301,000)
<DISCONTINUED>                                             0
<EXTRAORDINARY>                                            0
<CHANGES>                                                  0
<NET-INCOME>                                        (301,000)
<EPS-BASIC>                                          (647.82)<F2>
<EPS-DILUTED>                                        (647.82)<F2>

<FN>
<F1> Includes $2,528,000 of restricted cash.
<F2> Primary EPS and diluted EPS include $(323.91) per Preferred Unit of Limited
Partnership Interest.
</FN>

</TABLE>
Breadcrumb

1. Home

2. Print 

3. Pdf 

4. Node 

5. Entity Print 

Detections of Highly Pathogenic

Avian Influenza in Mammals

Last Modified: 

Print

There are many species that are potentially susceptible to highly pathogenic avian

influenza (HPAI). In addition to birds and poultry, H5N1 viruses have been detected

in some mammals (see list below). Infection may cause illness, including severe

disease and death in some cases.
Loading...

Table Notes

Date Detected: Indicates the date when a positive detection was obtained by the

development a l RRT PCR targeting the Eurasian lineage goose/Guangdong H5 clade 2.3.4.4b.

HPAI Strain:

EA = Eurasian; AM = North American; the EA H5 (2.3.4.4) viruses are highly pathogenic to

poultry.

EA/AM: reassortant of H5 goose/Guangdong and North American wild bird lineage

Virus lineage, subtype, and pathotype per cleavage site analysis are determined from

sequence data direct from the sample or virus isolate. An incomplete subtype indicates either

(1) the specimen is pending virus isolation and/or sequencing results, or (2) the specimen was

detected by the developmental H5 RRT PCR targeting the Eurasian lineage goose/Guangdong

H5 clade 2.3.4.4b but could not be further characterized, often due to a low level of virus or

viral RNA present in a given sample.
About Avian Influenza

Avian influenza is caused by influenza Type A virus (influenza A). Avian-origin

influenza viruses are broadly categorized based on a combination of two groups of

proteins on the surface of the influenza A virus: hemagglutinin or “H” proteins, of

which there are 16 (H1–H16), and neuraminidase or “N” proteins, of which there are

9 (N1–N9). Many different combinations of “H” and “N” proteins are possible. Each

combination is considered a different subtype, and related viruses within a subtype

may be referred to as a lineage. Avian influenza viruses are classified as either “low

pathogenic” or “highly pathogenic” based on their genetic features and the severity

of the disease they cause in poultry. Most viruses are of low pathogenicity, meaning

they cause no signs or only minor clinical signs of infection in poultry.

Related Links

Avian Influenza

Confirmations of HPAI in Commercial and Backyard Flocks

Detections of HPAI in Wild Birds
Breadcrumb

1. Home

2. Print 

3. Pdf 

4. Node 

5. Entity Print 

Adverse Event Reporting

Last Modified: 

Print

An adverse event is any undesirable occurrence after the use of an

immunobiological product, including illness or reaction, whether or not the event

was caused by the product. For products intended to diagnose disease, adverse

events refer to anything that hinders discovery of the correct diagnosis.

The mission of the Center for Veterinary Biologics (CVB) is to ensure that animal

immunobiologics are in compliance with the Virus-Serum-Toxin Act. Reports are

assessed for the possibility of a product deficiency. When necessary, testing is

performed or additional information sought. The CVB is, however, unable to make

diagnoses or recommendations specific to individual cases. Some of the

manufacturers do provide such services. Receipt of a report by the CVB does not

necessarily imply that the product caused an adverse event, or even that a

particular event actually occurred.

The manufacturer is required to report all adverse events they receive to the CVB.

Please contact the manufacturer to report adverse events.

Please note that reporting adverse events to the manufacturer cannot be

done from this website. You will need to contact the manufacturer directly.

A contact telephone number may be available on the label of the product or on the

manufacturer’s website.
Reporting Adverse Events for Pharmaceuticals or

Insecticides

Veterinary drugs, medicated feeds, and animal devices are regulated by the

U.S. Food and Drug Administration (FDA) Center for Veterinary Medicine (CVM)

under the Food, Drug, and Cosmetic Act. The CVM recommends that you first

contact the manufacturer to report an adverse event. To contact the CVM

directly, call 888-FDA-VETS.

Topical insecticides—Most of the products used topically for the control of

ectoparasites and insects on animals are regulated by the U.S. Environmental

Protection Agency (EPA) under the Federal Insecticide Fungicide and

Rodenticide Act. To contact the EPA directly, call 800-858-7378.

If unable to report an adverse event to the manufacturer of an animal

immunobiologic product regulated by the CVB, you may contact us using

one of the methods below.

Online (preferred method): USDA Adverse Event Reporting—use form "Public

Adverse Event Report"

Instructional Guidance for PV Express II for Public Submissions (745.04 KB)

Fax or Mail: Download and complete the Adverse Event Report Form (APHIS

2080) (258.76 KB) and fax to 515-337-6120 or submit to us by mail at Center

for Veterinary Biologics, 1920 Dayton Ave., P.O. Box 844, Ames, IA 50010.

Phone: Call the CVB at 800-752-6255.

More Information

See frequently asked questions on adverse event reporting/pharmacovigilance.

Are you a manufacturer looking for guidance? Go to Adverse Events Industry

Guidance for Compliance to 9 CFR 116.9.
#### State v. Wong Yuen.

18499

8/21/96

Affirmed
# C_2016203EN.01002501.xml

| 7.6.2016 | EN | Official Journal of the European Union | C 203/25 |
| --- | --- | --- | --- |

7.6.2016

EN

Official Journal of the European Union

C 203/25

---

Article 55

The Member States shall communicate or cause to be communicated to the Agency all the information necessary to enable it to exercise its right of option and its exclusive right to conclude supply contracts.

---
<PAGE>


                                                                    EXHIBIT 99.1


                            CERTIFICATION PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

         In connection with the Annual Report of 1999 Broadway Associates
Limited Partnership; (the "Partnership"), on Form 10-KSB for the annual period
ended December 31, 2002, as filed with the Securities and Exchange Commission on
the date hereof (the "Report"), the undersigned, in the capacities and on the
date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: (1) the
Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities and Exchange Act of 1934; and (2) the information contained in the
Report fairly presents, in all material respects, the financial condition and
results of operations of the Partnership.


Date: March 28, 2003                                   /s/ Michael L. Ashner
                                                       -----------------------
                                                       Michael L. Ashner
                                                       Chief Executive Officer


Date: March 28, 2003                                   /s/ Thomas Staples
                                                       -----------------------
                                                       Thomas Staples
                                                       Chief Financial Officer
# EUR-Lex - 22003A1223(01) - EN

Avis juridique important

*|*

# 22003A1223(01)

**Agreement between the European Community and Australia amending the Agreement on trade in wine **

*
Official Journal L 336 , 23/12/2003 P. 0100 - 0100 *

Agreement

between the European Community and Australia amending the Agreement on trade in wine

THE EUROPEAN COMMUNITY, hereinafter referred to as "the Community", of the one part,

and

AUSTRALIA, of the other part,

Having regard to the Agreement between the Community and Australia on trade in wine, signed in Brussels and Canberra respectively on 26 and 31 January 1994, as last amended by the Agreement of 6 August 2002,

Whereas:

Annex I, point 1(b) of that Agreement authorises the use of cation exchange resins for the purpose of stabilising Australian wines imported and marketed in the Community; this authorisation is granted provisionally until 30 June 2003.

Pending a final decision on treatment with cation exchange resins, the authorisation of this treatment for Australian wines should be extended until 30 June 2004,

HAVE AGREED AS FOLLOWS:

Article 1

The Agreement between the European Community and Australia on trade in wine, signed in Brussels and Canberra respectively on 26 and 31 January 1994, as last amended by the Agreement of 6 August 2002, is hereby amended as follows:

In Annex I, point 1(b), the date "30 June 2003" is replaced by "30 June 2004".

Article 2

This Agreement shall enter into force on 1 July 2003.

Article 3

This Agreement is drawn up in duplicate in the Spanish, Danish, German, Greek, English, French, Italian, Dutch, Portuguese, Finnish and Swedish languages, each text being equally authentic.

IN WITNESS WHEREOF, the undersigned have signed this Agreement.

Done at Brussels, 10 December 2003.

For Australia

Michael J. Taylor

For the European Community

José Manuel Silva Rodriguez
Exhibit







Exhibit 10.1





Description of Compensation Arrangements for Independent Directors
 


Effective June 1, 2018, which will be the start of the Board’s annual pay cycle, Marsh & McLennan Companies, Inc. (the "Company") will compensate its independent directors as follows:


Basic Annual Retainer.  All independent directors will receive a basic annual retainer of $120,000. 
 
Annual Stock Grant.  On June 1 of each year, all independent directors will receive an annual grant of the Company’s common stock with a market value of $175,000 on the grant date.
 
Supplemental Annual Retainers for Audit and Compensation Committee Chairs.  The chairs of the Board’s audit and compensation committees will each receive a supplemental annual retainer of $25,000.


Supplemental Annual Retainers for Committee Chairs.  The chairs of the Board’s finance, directors and governance and corporate responsibility committees will each receive a supplemental annual retainer of $15,000.
 
Supplemental Annual Retainer for Non-Executive Chairman.  The Board’s independent chairman will receive a supplemental annual retainer of $200,000. 


Under the terms of the Company’s Directors’ Stock Compensation Plan, each director may elect to receive his or her basic annual retainer and any supplemental annual retainer in cash, common stock or a combination thereof.